← Leaderboards
Joshua Jeffrey Field
Dana-Farber Cancer Inst
$4,942,728
Attributed
$17,095,968
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2011–16$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$15,528,968 · 3
FDA$1,567,000 · 1
By mechanism
P50$10,797,309 · 1
R01$5,616,591 · 2
R34$682,068 · 1
Top collaborators
- David G. Nathan12 shared
- Joel M. Linden10 shared
- Jonathan R Lindner5 shared
- Michael Rutledge Debaun4 shared
- Donna S. Neuberg4 shared
- Klaus F. Ley2 shared
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungClinical TrialsFda ApprovedPharmaceutical PreparationsSickle Cell AnemiaIschemiaEventPrincipal InvestigatorAgonistBloodReceptorInflammationResearch PersonnelSeveritiesCellsCollaborationsSickle CellBlood FlowPainMonitorOutcome MeasureInjuryLeukocytesUltrasonography
Grant awards (16)
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,004,198
P50 · FY2016 · HL
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$799,323
R01 · FY2016 · HL
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia$632,580
R01 · FY2016 · FD
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,108,843
P50 · FY2015 · HL
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$787,224
R01 · FY2015 · HL
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia$280,832
R01 · FY2015 · FD
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,181,100
P50 · FY2014 · HL
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$788,408
R01 · FY2014 · HL
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia$256,993
R01 · FY2014 · FD
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,220,754
P50 · FY2013 · HL
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$770,409
R01 · FY2013 · HL
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia$396,595
R01 · FY2013 · FD
A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia$2,282,414
P50 · FY2012 · HL
Biomarkers of Inflammation and Vaso-occlusion in Sickle Cell Disease$904,227
R01 · FY2012 · HL
A Feasibility Study of Regadenoson for the Treatment of Acute Chest Syndrome$341,034
R34 · FY2012 · HL
A Feasibility Study of Regadenoson for the Treatment of Acute Chest Syndrome$341,034
R34 · FY2011 · HL